Health conditions
(Data source: WHO)
-C61 Malignant neoplasm of prostate
Malignant neoplasm of prostate;C61 ;Malignant neoplasm of prostate
Interventions (Data source: WHO)
Investigational product, dose and mode of administration: ODM-201 600 mg or placebo (2 x 300 mg tablets) bid orally with food.
Duration of treatment: Until confirmed metastasis or until death up to 72 months (6 years).
The study treatment will be given in conjunction with the current hormonal treatment, if such treatment has been prescribed to participants. The cost of that treatment will be covered by Sponsor.
Inclusion/Exclusion Criteria
(Data source: WHO)
Gender: Male
Maximum age: 99
Minimum age: 18
Inclusion criteria:
Among inclusion criteria are the following, please refer to the protocol for the rest of criteria:
1.Written informed consent obtained.
2.Males aged 18 years.
3.Histologically or cytologically confirmed adenocarcinoma of prostate without neuroendocrine differentiation or small cell features.
4.Progressive castration-resistant prostate cancer is defined as 3 consecutive rising PSA level during androgen deprivation therapy (ADT) at least 1 week apart, resulting in 2 > 50% increases over nadir, with the last value 2 ng/ml despite castrate level of serum testosterone. If the patient has a history of antiandrogen use, the most recent PSA value must be obtained at least 4 weeks after antiandrogen withdrawal.
5.Castrate level of serum testosterone (< 1.7 nmol/l [50 ng/dl]) on gonadotropin releasing hormone (GnRH) agonist or antagonist therapy or after bilateral orchiectomy. Patients who have not undergone bilateral orchiectomy must continue GnRH therapy during the study.
6.PSADT of 10 months and PSA 2 ng/ml at screening.
7.Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Exclusion criteria:
Among exclusion criteria are the following, please refer to the protocol for the rest of criteria:
1.History of metastatic disease or presence of detectable metastases by blinded central reading. Presence of pelvic lymph nodes < 2 cm in short axis below the aortic bifurcation is allowed.
2.Symptomatic local-regional disease that requires medical intervention including moderate/severe urinary obstruction or hydronephrosis due to prostate cancer
3.Acute toxicities of prior treatments and procedures not resolved to grade 1 or baseline before randomisation.
4.Prior treatment with:
?second generation androgen receptor (AR) inhibitors such as enzalutamide, ARN-509, ODM-201, other investigational AR inhibitors,
?CYP17 enzyme inhibitor such as abiraterone acetate, TAK-700 or
?oral ketoconazole longer than for 28 days.
5.Use of estrogens, 5-α reductase inhibitors (finasteride, dutasteride) or AR inhibitors (bicalutamide, flutamide, nilutamide, cyproterone acetate) within 28 days before randomisation.
6.Prior chemotherapy or immunotherapy for prostate cancer, except adjuvant/neoadjuvant treatment completed > 2 years before randomisation.
-
Further information on trial
Date trial registered
Apr 29, 2015
Incorporation of the first participant
Apr 9, 2015
Recruitment status
Complete
Academic title
(Data source: WHO)
A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF ODM-201 IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Type of trial
(Data source: WHO)
Interventional
Design of the trial
(Data source: WHO)
This is a randomised, phase III, multicentre, double-blind, placebo-controlled efficacy and safety study of oral ODM-201 in patients with nmCRPC who are at high risk for developing metastatic disease. The study has a design of 2 parallel groups and consists of 2 periods: a study treatment period and a follow-up period.
All eligible patients will be randomised to receive 600 mg of ODM-201 twice a day (bid) or placebo in a 2:1 ratio in a double-blind manner. Randomisation will be stratified by PSA doubling time (PSADT; 6 months vs. > 6 months) and use of osteoclast-targeted therapy (yes vs. no).
The study treatment will be given in conjunction with the current hormonal treatment, if such treatment has been prescribed to participants. The cost of that treatment will be covered by Sponsor.
Phase
(Data source: WHO)
III
Contact information
(Data source: WHO)
ORION CORPORATION, ORION PHARMA
Trial results
(Data source: WHO)
Results summary
no information available yet
Link to the results in the primary register
no information available yet
Information on the availability of individual participant data
no information available yet
Trial sites
Countries
(Data source: WHO)
Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Finland, France, Germany, Greece, Hungary, Israel, Italy, Korea South, Latvia, Netherlands, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kindgdom, United States
Contact for further information on the trial
Contact for general information
(Data source: WHO)
Rosa
Chamorro
Calle Amador Merino Reyna N? 223 Int. 802, Urb. Jardin
BAYER S.A.
202 5636, 985 630 426
rosa.chamorro@iconplc.com
Contact for scientific information
(Data source: WHO)
Rosa
Chamorro
Calle Amador Merino Reyna N? 223 Int. 802, Urb. Jardin
BAYER S.A.
202 5636, 985 630 426
rosa.chamorro@iconplc.com
Back to overview